INmune Bio Inc. (NASDAQ: INMB) announced today that additional analyses from its Phase 2 MINDFuL trial evaluating XPro™, a ...

Notably, the remission rate (DAS28-CRP <2.6) for CPL’116 240 mg exceeded 45% throughout ... alanine aminotransferase (ALT), ...

The most common reason was a positive ANA, and the other common reasons included elevated erythrocyte sedimentation rate, ...

The American Red Cross declared a national blood shortage this week — and said that climate disasters and low donor turnout are part of the problem.